Table I.
FVIII/VWF concentrates available in Italy for VWD treatment.
| Product | Purification | Viral inactivation | Specific activity#(U/mg protein) | VWF:RCo/Ag (ratio) | VWF:RCo/FVIII:C (ratio) | Other proteins |
|---|---|---|---|---|---|---|
| Alphanate (Grifols, Los Angeles, USA) | Affinity chromatography (heparin) | Solvent/detergent + 72 h at 80 °C | >100 | 0.94 | 1.21 | Albumin + |
| Fanhdi (Grifols, Barcelona, Spain) | Affinity chromatography (heparin) | Solvent/detergent + 72 h at 80 °C | >100 | 0.83 | 1.48 | Albumin + |
| Haemate® P (CSL Behring, Marburg, Germany) | Multiple precipitation | Pasteurisation 10 h at 60 °C | 40±6 | 0.96 | 2.54 | Albumin + |
| Immunate (Baxter, Wien, Austria) | Ion exchange chromatography | Detergent + vapour heat 10 h at 60 °C, 1 h at 80 °C | 100±50 | 0.47 | 1.10 | Albumin + |
| Wilfactin (LFB, France) | Aluminium hydroxide gel adsorption ion exchange + Affinity chromatography | Solvent/detergent; dry heat; 72 h at 80 °C; 35 nm nanofiltration | ≥50* | 0.95 | >10 | Albumin + |
#
Specific activity measured as FVIII before the addition of albumin as stabiliser.
*
Specific activity measured as VWF:RCo.